Octreotide is not effective in the acute treatment of migraine.

Octreotide is not effective in the acute treatment of migraine. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Octreotide is not effective in the acute treatment of migraine. Abstract Text:

M J Levy,M S Matharu,R Bhola,K Meeran,P J Goadsby,

The aim of this study was to determine whether subcutaneous octreotide is effective for the treatment of acute migraine. Patients with migraine with and without aura as classified by the International Headache Society were recruited to a double-blind placebo-controlled crossover study. Patients were instructed to treat two attacks of at least moderate pain severity, with at least a 7 day interval, using subcutaneous 100 microg octreotide or matching placebo. The primary endpoint was the headache response defined as: severe or moderate pain becomes mild or nil, at 2 h. The primary endpoint was analysed using a Multilevel Analysis approach. Secondary end-points included associated symptoms and a four-point functional disability score. The study was powered to detect a 30% difference at an alpha of 0.05 and a beta of 0.8. A total of 51 patients were recruited, of whom 42 provided efficacy data on an attack treated with octreotide and 41 with placebo. Modelling the headache response as a binomial determined by treatment, using the patient as the level 2 variable, and considering a possible period effect, and sex and migraine type as other variables of interest, subcutaneous octreotide was not significantly superior to placebo. The two hour headache response rates were 20% for placebo and 14% for octreotide, whilst the two hour pain free rates were 7% and 2%, respectively. Subcutaneous octreotide 100 microg is not effective in the acute treatment of migraine when compared to placebo.

Octreotide is not effective in the acute treatment of migraine. Publishing Authors By Initials

MJ Levy,MS Matharu,R Bhola,K Meeran,PJ Goadsby,

For similar polycyclic compounds: macrocyclic compounds: peptides, cyclic: octreotide research abstracts see: polycyclic compounds: macrocyclic compounds: peptides, cyclic: octreotide research

PUBMED ID PMID:

MEDLINE DATE:

Octreotide is not effective in the acute treatment of migraine. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Cephalalgia : an international journal of headache

VOLUME: 25

Page Numbers: 48-55

Journal Abbreviation: Cephalalgia

ISSN: 0333-1024

DAY: 11

MONTH: Jan

YEAR: 2005

Octreotide is not effective in the acute treatment of migraine. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8200710

Octreotide is not effective in the acute treatment of migraine. Keywords Mesh Terms:

KEYWORDS: Octreotide

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Octreotide is not effective in the acute treatment of migraine. Information

Substance Name: Octreotide

Registry Number: 83150-76-9

Grant and Affiliation Information for Octreotide is not effective in the acute treatment of migraine.

AFFILIATION: Headache Group, Institute of Neurology, London, UK.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cephalalgia

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Octreotide is not effective in the acute treatment of migraine Related Publications

• Abnormal blink reflex studies in a patient with supraorbital neuralgia.
• Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat.
• Are triptans with enhanced lipophilicity used for the acute treatment of migraine associated with an increased consulting rate for depressive illness?
• Benign cough headache.
• Bilateral paroxysmal hemicrania or bilateral paroxysmal cephalalgia, another novel indomethacin-responsive primary headache syndrome?
• Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era?
• Chronic headache and pituitary tumors.
• Cluster headache: new perspectives.
• Diffusion- and perfusion-weighted MR imaging in persistent migrainous visual disturbances.
• Dopamine and migraine: biology and clinical implications.
• Familial SUNCT.
• How do the currently used prophylactic agents work in migraine?
• Is a central action of acute antimigraine drugs essential?
• Migraine management: contrasting patient preferences with current clinical end points: introduction.
• Neuropeptides and migraine--a useful biological marker?
• Neuropeptides in migraine and cluster headache.
• Neurostimulation in primary headache syndromes.
• Neurovascular headache and a midbrain vascular malformation: evidence for a role of the brainstem in chronic migraine.
• Octreotide is not effective in the acute treatment of migraine.
• Paroxysmal hemicrania in a family.
• Paroxysmal hemicrania: a prospective clinical study of 31 cases.
• Placebo response in cluster headache trials: a review.
• Rizatriptan in acute treatment of migraine: update on new comparative data.
• SUNCT syndrome in the elderly.
• The mode of action of sumatriptan is vascular? A debate.
• The paroxysmal hemicrania-tic syndrome.
• Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.
• Unilateral photophobia or phonophobia in migraine compared with trigeminal autonomic cephalalgias.
• Update on the prophylaxis of migraine.
• What is the physiological role of the trigeminovascular system?